Total Payments
$2,548
2024 Payments
$484.68
Companies
17
Transactions
114
Medicare Patients
875
Medicare Billing
$119,031
Payment Breakdown by Category
Food & Beverage$2,536 (99.5%)
Education$11.71 (0.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,536 | 113 | 99.5% |
| Education | $11.71 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $869.42 | 41 | $0 (2024) |
| Novo Nordisk Inc | $615.92 | 29 | $0 (2024) |
| Antares Pharma, Inc. | $320.74 | 12 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $213.45 | 6 | $0 (2023) |
| Abbott Laboratories | $99.39 | 5 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $85.75 | 4 | $0 (2023) |
| Medtronic, Inc. | $85.27 | 4 | $0 (2022) |
| GlaxoSmithKline, LLC. | $61.71 | 3 | $0 (2023) |
| RECORDATI_RARE_DISEASES_INC. | $37.90 | 2 | $0 (2023) |
| Tandem Diabetes Care, Inc. | $28.40 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $484.68 | 21 | Lilly USA, LLC ($260.29) |
| 2023 | $1,005 | 45 | Lilly USA, LLC ($400.26) |
| 2022 | $571.53 | 25 | Antares Pharma, Inc. ($221.51) |
| 2021 | $444.43 | 21 | Novo Nordisk Inc ($260.57) |
| 2019 | $19.24 | 1 | Shire North American Group Inc ($19.24) |
| 2018 | $22.81 | 1 | GlaxoSmithKline, LLC. ($22.81) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/17/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Diabetes | ||||||
| 07/11/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $26.83 | General |
| Category: Diabetes | ||||||
| 07/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Diabetes | ||||||
| 06/27/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: Diabetes | ||||||
| 06/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Diabetes | ||||||
| 06/12/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 06/12/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Diabetes | ||||||
| 06/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Diabetes | ||||||
| 06/05/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $32.22 | General |
| Category: Obesity | ||||||
| 05/09/2024 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 05/07/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.53 | General |
| Category: Diabetes | ||||||
| 04/25/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Diabetes | ||||||
| 04/24/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $22.82 | General |
| 04/23/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 03/18/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Diabetes | ||||||
| 02/27/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: Diabetes | ||||||
| 02/14/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Diabetes | ||||||
| 01/29/2024 | Antares Pharma, Inc. | TLANDO (Drug), XYOSTED | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 01/24/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $26.53 | General |
| Category: Diabetes | ||||||
| 01/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: Diabetes | ||||||
| 12/19/2023 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: Obesity | ||||||
| 12/16/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Diabetes | ||||||
| 12/12/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Diabetes | ||||||
| 12/11/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 365 | 571 | $137,623 | $47,401 |
| 2022 | 4 | 256 | 401 | $95,012 | $36,049 |
| 2021 | 5 | 235 | 315 | $81,726 | $33,032 |
| 2020 | 1 | 19 | 19 | $5,700 | $2,549 |
Total Patients
875
Total Services
1,306
Medicare Billing
$119,031
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 162 | 333 | $86,396 | $33,587 | 38.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 73 | 73 | $26,700 | $9,314 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 34 | $6,158 | $2,253 | 36.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $4,125 | $1,184 | 28.7% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 70 | 96 | $14,045 | $894.88 | 6.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 16 | 20 | $200.00 | $168.00 | 84.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 122 | 243 | $61,236 | $24,188 | 39.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 71 | 71 | $21,300 | $9,498 | 44.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 19 | 24 | $3,259 | $1,760 | 54.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 44 | 63 | $9,217 | $603.20 | 6.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 122 | $30,744 | $13,060 | 42.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 92 | 92 | $27,600 | $12,292 | 44.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 23 | 43 | $10,836 | $3,630 | 33.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 13 | 13 | $3,900 | $1,551 | 39.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 12 | $3,528 | $1,309 | 37.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 13 | $2,192 | $995.81 | 45.4% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 19 | 20 | $2,926 | $194.20 | 6.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 19 | 19 | $5,700 | $2,549 | 44.7% |
About Dr. Mohamed Ali, MD
Dr. Mohamed Ali, MD is a Obesity Medicine healthcare provider based in Goshen, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/30/2015. The National Provider Identifier (NPI) number assigned to this provider is 1568857415.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohamed Ali, MD has received a total of $2,548 in payments from pharmaceutical and medical device companies, with $484.68 received in 2024. These payments were reported across 114 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($2,536).
As a Medicare-enrolled provider, Ali has provided services to 875 Medicare beneficiaries, totaling 1,306 services with total Medicare billing of $119,031. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Obesity Medicine
- Other Specialties Diabetes & Metabolism
- Location Goshen, NY
- Active Since 03/30/2015
- Last Updated 02/20/2023
- Taxonomy Code 2080B0002X
- Entity Type Individual
- NPI Number 1568857415
Products in Payments
- MOUNJARO (Drug) $440.66
- Ozempic (Drug) $320.41
- JARDIANCE (Drug) $231.61
- NOCDURNA (Drug) $226.05
- FARXIGA (Drug) $195.67
- XYOSTED (Drug) $166.95
- RYBELSUS (Drug) $139.50
- Rybelsus (Drug) $102.38
- FREESTYLE LIBRE (Device) $99.39
- TRULICITY (Drug) $74.40
- ZEPBOUND (Drug) $53.31
- InPen (Device) $44.94
- SIGNIFOR LAR (Drug) $37.90
- TRELEGY ELLIPTA (Drug) $37.47
- Saxenda (Drug) $36.77
- BAQSIMI (Drug) $34.91
- t:slim X2 Insulin Pump with Control-IQ (Device) $28.40
- INPEN SMART INSULIN DELIVERY SYSTEM (Device) $27.04
- SHINGRIX (Biological) $24.24
- Pomalyst (Drug) $22.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.